Clinical Trials · NCT06865677
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 2
- Start date
- Jun 2025
- Locations
- 1 site, United States
- Primary endpoint
- Overall Response Rate (Partial Response or Complete Response) of Sacituzumab Govitecan in Participants With Recurrent Gynecological Malignancies, Calculated for Each Individual Tumor Histology by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1